4 ms·
I can't remember the source, but I think this only rules out small-dose, oral. There will still be a trial with large-dose, injectable.
by megaman821 11mo ago
I can't remember the source, but I think this only rules out small-dose, oral. There will still be a trial with large-dose, injectable.
- burnt-resistor 11mo agoFor reference in typical maintenance doses: - Rybelsus (type-2 diabetes; oral semaglutide 14 mg/day; much less bioavailability) - Wegovy (obesity; injectable semaglutide 2.4 mg/wk) - Ozempic (type-2 diabetes; injectable semaglutide 1.0 mg/wk)
- Mariehane 11mo agoWill there be a large-dose trial? I imagine that’s going to be more difficult, as the weight-loss effect of GLP-1 means you cant include frail patients in your target group. And GLP-1 at high doses also has some unfavourable side-effects: nausea, vomiting, diarrhea, constipation.
- astrange 11mo agoIndeed, and it's literally not Ozempic but Rybelsus.